CXCR4 Peptide Conjugated Au-Fe₂O₃ Nanoparticles for Tumor-targeting Magnetic Resonance Imaging

Abstract

Peptide-functionalized Au-Fe₂O₃ nanoparticles(termed as anti-CXCR4-Au-Fe₂O₃ NPs) have been constructed through conjugation of dumbbell-like Au-Fe₂O₃ NPs with C-X-C motif chemokine receptor 4(CXCR4) binding cyclic peptide. One dumbbell-like Au-Fe₂O₃ NP composes an Au NP[(3.3±0.3) nm in diameter] for conjugating CXCR4 binding cyclic peptide through Au-S covalent bond and a Fe₂O₃ NP[(8.7±0.8) nm in diameter] for using as T ₂-weighted magnetic resonance imaging(MRI) contrast agent. The anti-CXCR4-Au-Fe₂O₃ NPs have reasonable biocompatibility and integration of T ₂-weighted MRI contrast and tumor-targeting functionalities. The anti-CXCR4-Au-Fe₂O₃ NPs exhibit strong interactions with two kinds of breast tumor cells, MCF-7 cells and MDA-MB-231 cells, and high negative contrast in MRI of MDA-MB-231 tumor bearing mouse with 62% decreasing of MRI signal, indicating that the anti-CXCR4-Au-Fe₂O₃ NPs can recognize tumor with high efficacy and specificity.

Keywords

Dumbbell-like Au-Fe₂O₃ nanoparticle / C-X-C motif chemokine receptor 4 / Cyclic peptide / T ₂-Weighted magnetic resonance imaging / Tumor targeting ability

References

[1] Dempsey M. F., Condon B., Hadley D. M. Seminars in Ultrasound, CT and MRI, 2002, 23(5): 392.

[2] Willinek W. A., Schild H. H. Eur. J. Radiol., 2008, 65(1): 2.

[3] Li D. Z., Chen H. D., Bi F., Wang Z. X. Chin. J. Anal. Chem., 2016, 44(10): 1609.

[4] Shao Y. P., Cherry S. R., Farahani K., Meadors K., Siegel S., Silverman R. W., Marsden P. K. Phys. Med. Biol., 1997, 42(10): 1965.

[5] Baker M. Nature, 2010, 463(7283): 977.

[6] Baker M. Nat. Methods, 2010, 7(12): 957.

[7] Lee D. E., Koo H., Sun I. C., Ryu J. H., Kim K., Kwon I. C. Chem. Soc. Rev., 2012, 41: 2656.

[8] Ling D., Lee N., Hyeon T. Acc. Chem. Res., 2015, 48(5): 1276.

[9] Shen Z. Y., Wu A. G., Chen X. Y. Mol. Pharmaceutics, 2017, 14(5): 1352.

[10] Schleich N., Po C., Jacobs D., Ucakar B., Gallez B., Danhier F., Préat V. J. Controlled Release, 2014, 194(28): 82.

[11] Chen F., Cai W. B. Small, 2014, 10(10): 1887.

[12] Shi S. X., Yang K., Hong H., Chen F., Valdovinos H. F., Goel S., Barnhart T. E., Liu Z., Cai W. B. Biomaterials, 2015, 39: 39.

[13] Liu J. X., Chen H. D., Fu Y., Li X. D., Chen Y. X., Zhang H. M., Wang Z. X. J. Mater. Chem. B, 2017, 5: 8554.

[14] Morshed R. A., Muroski M. E., Dai Q., Wegscheid M. L., Auffinger B., Yu D., Han Y., Zhang L., Wu M., Cheng Y., Lesniak M. S. Mol. Pharmaceutics, 2016, 13(6): 1843.

[15] Chen H. D., Li X. D., Liu F. Y., Zhang H. M., Wang Z. X. Mol. Pharmaceutics, 2017, 14(9): 3134.

[16] Sharma S., Kotamraju V. R., Mölder T., Tobi A., Teesalu T., Ruoslahti E. Nano Lett., 2017, 17(3): 1356.

[17] Li T., Mello-Thoms C., Brennan P. C. Breast Cancer Res. Treat., 2016, 159(3): 395.

[18] de Clercq E. Nat. Rev. Drug Discovery, 2003, 2(7): 581.

[19] Demmer O., Dijkgraaf I., Schumacher U., Marinelli L., Cosconati S., Gourni E., Wester H. J., Kessler H. J. Med. Chem., 2011, 54(21): 7648.

[20] Demmer O., Frank A. O., Hagn F., Schottelius M., Marinelli L., Cosconati S., Brack-Werner R., Kremb S., Wester H. J., Kessler H. Angew. Chem., Int. Ed., 2012, 51(32): 8110.

[21] Maro S. D., Trotta A. M., Brancaccio D., Leva F. S. D., Pietra V. L., Ieranò C., Napolitano M., Portella L., D’Alterio C., Siciliano R. A., Sementa D., Tomassi S., Carotenuto A., Novellino E., Scala S., Marinelli L. J. Med. Chem., 2016, 59(18): 8369.

[22] Yang M., Cheng K., Qi S. B., Liu H. G., Jiang Y. X., Jiang H., Li J. B., Chen K., Zhang H. M., Cheng Z. Biomaterials, 2013, 34: 2796.

[23] Yu H., Chen M., Rice P. M., Wang S. X., White R. L., Sun S. H. Nano Lett., 2005, 5(2): 379.

[24] Xu C. J., Xie J., Ho D., Wang C., Kohler N., Walsh E. G., Morgan J. R., Chin Y. E., Sun S. H. Angew. Chem., Int. Ed., 2008, 47(1): 173.

[25] Cheng K., Yang M., Zhang R. P., Qin C. Q., Su X. H., Cheng Z. ACS Nano, 2014, 8(10): 9884.